Cabometyx (cabozantinib tablet)

News alerts, weekly reports and conference planners

Company:

Exelixis, Ipsen, Takeda

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
No biomarker	Thyroid Gland Carcinoma	No biomarker	Thyroid Gland Carcinoma	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A2 - Guideline nivolumab + cabozantinib tablet Sensitive : A2	nivolumab + cabozantinib tablet Sensitive: A2 - Guideline nivolumab + cabozantinib tablet Sensitive : A2
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	nivolumab + cabozantinib tablet Sensitive: A2 - Guideline nivolumab + cabozantinib tablet Sensitive : A2	nivolumab + cabozantinib tablet Sensitive: A2 - Guideline nivolumab + cabozantinib tablet Sensitive : A2
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: B - Late Trials nivolumab + cabozantinib tablet Sensitive : B	nivolumab + cabozantinib tablet Sensitive: B - Late Trials nivolumab + cabozantinib tablet Sensitive : B
AXL-L	Renal Cell Carcinoma	AXL-L	Renal Cell Carcinoma	cabozantinib tablet Sensitive: B - Late Trials cabozantinib tablet Sensitive : B	cabozantinib tablet Sensitive: B - Late Trials cabozantinib tablet Sensitive : B
HGF elevation	Hepatocellular Cancer	HGF elevation	Hepatocellular Cancer	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B
CXCL8 elevation	Hepatocellular Cancer	CXCL8 elevation	Hepatocellular Cancer	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B
MET elevation	Hepatocellular Cancer	MET elevation	Hepatocellular Cancer	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B
ANGPT2 elevation	Hepatocellular Cancer	ANGPT2 elevation	Hepatocellular Cancer	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	atezolizumab + cabozantinib tablet Sensitive: B - Late Trials atezolizumab + cabozantinib tablet Sensitive : B	atezolizumab + cabozantinib tablet Sensitive: B - Late Trials atezolizumab + cabozantinib tablet Sensitive : B
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials nivolumab + ipilimumab + cabozantinib tablet Sensitive : B	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials nivolumab + ipilimumab + cabozantinib tablet Sensitive : B
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials nivolumab + ipilimumab + cabozantinib tablet Sensitive : B	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials nivolumab + ipilimumab + cabozantinib tablet Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	atezolizumab + cabozantinib tablet Sensitive: B - Late Trials atezolizumab + cabozantinib tablet Sensitive : B	atezolizumab + cabozantinib tablet Sensitive: B - Late Trials atezolizumab + cabozantinib tablet Sensitive : B
TFE3 translocation	Renal Cell Carcinoma	TFE3 translocation	Renal Cell Carcinoma	cabozantinib tablet Sensitive: C2 – Inclusion Criteria cabozantinib tablet Sensitive : C2	cabozantinib tablet Sensitive: C2 – Inclusion Criteria cabozantinib tablet Sensitive : C2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	cabozantinib tablet Sensitive: C2 – Inclusion Criteria cabozantinib tablet Sensitive : C2	cabozantinib tablet Sensitive: C2 – Inclusion Criteria cabozantinib tablet Sensitive : C2
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3
MET elevation	Cholangiocarcinoma	MET elevation	Cholangiocarcinoma	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3
TIMP1-L	Cholangiocarcinoma	TIMP1-L	Cholangiocarcinoma	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3
ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3
RET fusion	Thyroid Gland Papillary Carcinoma	RET fusion	Thyroid Gland Papillary Carcinoma	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3

Cabometyx (cabozantinib tablet)

Associations
(74)

Associations
(74)

Cabometyx (cabozantinib tablet)

Associations(74)

Associations(74)

Associations
(74)

Associations
(74)